mk-2206
Aggressive NK-cell Leukemia
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Aggressive NK-cell Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide The Affiliated Hospital of Xuzhou Medical University | Phase 2 | B |
Evomela St. Jude Children's Research Hospital | Phase 2 | CCC |
Thiotepa St. Jude Children's Research Hospital | Phase 2 | CCC |
Anti-Thymoglobulin, Rabbit St. Jude Children's Research Hospital | Phase 2 | CCC |
Blinatumomab St. Jude Children's Research Hospital | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
mk-2206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →